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Abstract
Background: Understanding the efficacy and safety profile of antiepileptic drugs (AEDs) in feline epilepsy is a
crucial consideration for managing this important brain disease. However, there is a lack of information about the
treatment of feline epilepsy and therefore a systematic review was constructed to assess current evidence for the
AEDs’ efficacy and tolerability in cats. The methods and materials of our former systematic reviews in canine
epilepsy were mostly mirrored for the current systematic review in cats. Databases of PubMed, CAB Direct and
Google scholar were searched to detect peer-reviewed studies reporting efficacy and/or adverse effects of AEDs in
cats. The studies were assessed with regards to their quality of evidence, i.e. study design, study population,
diagnostic criteria and overall risk of bias and the outcome measures reported, i.e. prevalence and 95% confidence
interval of the successful and affected population in each study and in total.
Results: Forty studies describing clinical outcomes of AEDs’ efficacy and safety were included. Only two studies
were classified as “blinded randomised controlled trials”. The majority of the studies offered high overall risk of bias
and described low feline populations with unclear diagnostic criteria and short treatment or follow-up periods.
Individual AED assessments of efficacy and safety profile showed that phenobarbital might currently be considered
as the first choice AED followed by levetiracetam and imepitoin. Only imepitoin’s safety profile was supported by
strong level of evidence. Imepitoin’s efficacy as well as remaining AEDs’ efficacy and safety profile were supported
by weak level of evidence.
Conclusions: This systematic review reflects an evidence-based assessment of the published data on the AEDs’
efficacy and safety for feline epilepsy. Currently, phenobarbital is likely to be the first-line for feline epileptic patients
followed by levetiracetam and imepitoin. It is essential that clinicians evaluate both AEDs’ effectiveness and
tolerability before tailoring AED to the individual patient. Further studies in feline epilepsy treatment are by far
crucial in order to establish definite guidelines for AEDs’ efficacy and safety.
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Background
There is a paucity of literature about feline epilepsy
compared to canine epilepsy, however epileptic seizures
are a common neurological manifestation in cats with
an estimated prevalence in a referral hospital population
of 0.5-3.5% [1, 2]. Idiopathic epilepsy (IE) has not been
studied in cats as thoroughly as in dogs but between
21-59% of cats presenting with recurrent seizures can
be diagnosed with IE [3–5].
Treatment between canine and feline epileptic patients
is rather different mainly due to the divergent safety
profile between the two species [6, 7] but it is acceptable
that in both species the effectiveness of an AED may out-
weigh its adverse effects, and therefore both the efficacy
and safety profile should be considered before choosing
the most appropriate AED(s) for patients [8].
Systematic reviews are powerful and objective tools to
evaluate AEDs’ efficacy as well as severity and incidence
of AEDs’ safety profile described in literature [9–12].
Guidelines with regards to AEDs’ efficacy and safety
have been established in canine epilepsy [13, 14] based
on previous systematic reviews and meta-analysis [8, 15].
However, such guidelines lack in feline epilepsy. The
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goal of this systematic review was to summarize and as-
sess the results of the current studies regarding AEDs’
efficacy and safety in cats and provide evidence on the
treatment of feline epilepsy.
Methods
The methodology followed in this study was based on
previous similar studies published by the authors [8, 15].
Search strategy
Studies evaluating or describing the effectiveness and
safety of an AED in cats were searched. As it was de-
scribed in our previous systematic reviews [8, 15], studies
were assessed based on four inclusion criteria adapted for
feline patients, i.e. type of study (any peer-reviewed study),
case definition (cats that were investigated and diagnosed
with confirmed or presumed idiopathic epilepsy), treat-
ment (cats treated with antiepileptic drugs only) and out-
come (description of efficacy or safety outcomes after
treatment). Final electronic searches were carried out on
21 June 2017 with no date or language restrictions and the
same databases were searched with the same search strat-
egies as it was described before [8, 15], i.e. Pub Med, CAB
Abstracts, Google Scholar and searching of articles,
proceedings and textbooks to identify reference lists of
published papers and proceedings of relevant scientific
conferences such as the annual American College of
Veterinary Internal Medicine forum and the European
College of Veterinary Neurology Symposium. The
search terms used for the electronic databases were also
the same as in our two previous systematic reviews on
canine [8, 15] but adapted for feline subjects, i.e. the
terms ‘dog’ and ‘canine’ were replaced by the terms ‘cat’
and ‘feline’, respectively.
Study Selection
The same two-stage screening process that was recruited
in our previous systematic reviews [8, 15] was used; in
summary, at stage 1, papers’ titles and abstracts were
only evaluated and at stage 2, full-length papers were
evaluated based on the inclusion criteria 2, 3 and 4 to
exclude the ones irrelevant to our outcomes.
Assessment of quality of evidence
As in our previous systematic reviews [8, 15], studies
were categorised based on their study design, i.e. “blinded
randomised clinical trials” (bRCTs), “blinded randomised
experimental laboratory animal studies” (bRELAS),
“non-blinded RCTs” (nbRCTs), “non-blinded randomised
ELAS” (nbRELAS), “non-randomised clinical trials”
(NRCTs), “non-randomised ELAS” (NRELAS), “uncon-
trolled clinical trials” (UCTs), “uncontrolled ELAS”
(UELAS), “case series and case reports [16, 17]”. In
addition, the same three-part system of evidence quality
evaluation to characterize weaknesses and strengths of
each study within each group was used as it was de-
scribed in our previous systematic reviews [8, 15], i.e.
“(a) study group sizes, (b) subject enrolment quality
and (c) overall risk of bias based on Cochrane [18] and
Syrcle’s [19] ‘risk of bias’ assessment tool in order to
provide an indicator of confidence associated with the
findings of each study”. All in all, bRCTs or bRELAS
with large population, clear and thorough diagnostic
criteria and low overall risk of bias were considered as
studies with the highest quality of evidence. Lastly, the
treatment or follow-up period was reported for each
study and was considered short or long if it was less or
more than 6 months, respectively.
Study group sizes
The same system that was reported in our previous sys-
tematic reviews [8, 15] was used to evaluate the popula-
tion size in each study, i.e. “(a) >50 subjects per group
(‘good’ number), (b) 20–50 subjects (‘moderate’ number),
(c) 10–19 subjects (‘small’ number) and (d) <10 subjects
(‘very small’ number)”.
Assessment of subject enrolment quality
Information with regards to the investigations used for
the diagnosis of IE were reviewed to assess the quality of
subject definition in each study as ‘well characterized’,
‘fairly characterized’, ‘poorly characterized’ or ‘unclear.’
As far as the ELAS are concerned, that included investi-
gations for describing non-epileptic healthy animals, two
categories were described, i.e. ‘clearly characterized’ and
‘unclear’. The systems used were adapted for feline patients
from our previous systematic reviews [8, 15]. The main dif-
ference is that for the “well characterized” category, tests
for infectious diseases (including feline leukemia virus, fe-
line immunodeficiency virus, feline infectious peritonitis,
toxoplasmosis) were also included but these were desirable
but not mandatory.
Assessment of overall risk of bias and level of the studies’
evidence
The same methodology followed in our previous system-
atic review was used [8], i.e. “the studies were assessed
based on the ‘risk of bias’ components and were cate-
gorised as presenting ‘high’, ‘low’ or ‘unclear’ risk for each
component. The components were the random sequence
generation, allocation concealment, blinding of partici-
pants, personnel and outcome assessment, completeness
of outcome data, selective reporting of outcomes, ran-
dom housing and baseline characteristics of cats (only
for ELAS) and other sources of bias”.
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Assessment of outcome measures
The outcome measure was the assessment of the effect-
iveness and tolerability of AED(s) administered in cats.
AEDs’ effectiveness
The assessment of the effectiveness was performed
based on our previous canine systematic review [15]. In
addition, the 95% confidence interval (CI) of the suc-
cessful population in each study was also calculated and
assessed as previously [15]; in summary, in each study,
the cats with ≥50% reduction in seizure frequency were
considered as successful cases and if the 95% CI of suc-
cessfully treated cases was within ranges greater than
50%, then it was assumed that the majority of the study
population was successfully treated.
AEDs’ safety
The adverse effects were categorised by organ system,
i.e. neurological, gastro-intestinal, etc. and types, i.e. type
I (dose-dependent) and type II (idiosyncratic or dose-
independent). The assessment of the safety was per-
formed based on our previous systematic review [8]; in
summary, the prevalence of the affected population in
each study (i.e. number of cats that experienced adverse
effects divided by the total size of the study population)
and proportion of specific adverse effects for each indi-
vidual AED (i.e. number of studies that reported a spe-
cific adverse effect divided by the total number of the
studies for this AED) were evaluated. A further outcome
measure was also added which was the proportion of
specific adverse effects for each AED based on the total
affected population (i.e. number of subjects that devel-
oped a specific adverse effect divided by the total popu-
lation size from all the studies). In addition, the 95% CI
of the affected population in each study was also calcu-
lated and assessed as previously [8]. If the 95% CI of the
affected cases was within ranges greater than 50%, then
it was considered that the majority of the study popula-
tion showed adverse effects.
Results
Description of studies
By 21 June 2017, a total number of 684 unique citations
were found; 676 articles and eight major conference ab-
stracts from manual and electronic searches. One hun-
dred seventy six items fulfilled stage 1 screening criteria,
of which, 40 final studies (published between 1973 and
2017) also fulfilled stage 2 selection criteria and were
therefore chosen for thorough evaluation. The process is
also shown via a flow diagram (Additional file 1). One
study included three different trials [20] and another
study included both a trial and a retrospective part [21].
The included studies represented 2/40 (5%) bRELAS, 1/40
(2.5%) nbRCT, 2/40 (5%) nbRELAS, 5/40 (12.5%) UCTs,
11/40 (27.5%) UELAS, 12/40 (30%) retrospective case
series and 7/40 (17.5%) case reports (Table 1). Overall, the
40 selected studies described 10 different AEDs. AEDs
were usually given orally in all but three studies, where
medication was given intraperitoneally or via transdermal
application.
Signalment and baseline characteristics of study subjects
Baseline characteristics, i.e. breed, age and sex, of feline
population were reported to some degree in all the stud-
ies. Signalment was reported in all the clinical studies,
with various breeds, both sexes and a wide range of ages
at study entry (range 0.25-19 years) being reported. The
most common reported breed was domestic shorthaired
cats followed by Birmans, domestic longhaired cats,
Siamese, Burmese, Bengals, Himalayan and Maine Coon.
Males were more commonly affected compared to fe-
males, though these results were not statistically exam-
ined in order to specifically report the prevalence of IE
on the grounds of sex.
Disease characterization and subject enrolment quality
In approximately half of the studies (19/40, 48%), the in-
clusion criteria for diagnosing IE (clinical studies) or
healthy cats (ELAS) were not well described (Table 1).
Three case reports, each one described an otherwise
healthy cat that was suspected with structural epilepsy
due to an anesthesia-related hypoxic event [22] or post-
tramatic/vascular event [23, 24]. However, these studies
were included in our review for evaluating the AED
safety profile, as their aim was to describe an AED-
related adverse effect that was unrelated to the cause of
the epilepsy.
Study group sizes
Many studies (36/40, 90%) assessed small or very small
study size groups (Table 1).
Methodological quality of included studies
Many studies (96%) showed high or unclear risk of bias
(Table 1).
AEDs efficacy and safety profile
As in our previous systematic reviews [8, 15], details of
studies’ data, characteristics and outcomes are summa-
rized in the manuscript with further details captured
in Additional file 2: Table S1, Tables 2, 3 and 4 and
Figs. 1, 2, 3 and 4.
Phenobarbital
Eight studies [4, 25–31] assessed the efficacy of pheno-
barbital as a monotherapy agent or in combination with
other AEDs (two studies), providing a total size of 137
cats. Based on the 95% CI, in all the studies but three
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[4, 26, 31] (63%), the majority of the study population
was treated successfully. In one of these studies though
[26], phenobarbital was only used to treat a specific
type of epileptic seizures in cats, i.e. feline auditory re-
active seizures (FARS), which might have biased the re-
sults for the drug’s overall efficacy to control seizures.
Twelve studies [22–28, 31–35] evaluated the safety pro-
file of phenobarbital, providing a total size of 147 cats.
Three studies documented type I adverse effects, including
dermatological and neurological signs, clinic-pathological
abnormalities, polyphagia [36], polydipsia (PD) and weight
loss (Additional file 2: Table S1). Four studies reported type
II adverse effects including clinic-pathological abnormal-
ities and lympho-reticular and gastrointestinal signs (GI)
signs (Additional file 2: Table S1). Three studies reported
that there were no adverse effects. Based on the 95% CI, in
all studies but two [27, 34] (83%), the majority of reported
population did not show adverse effects. The most
common adverse effect was sedation and the least common
were behavioral changes, pruritus, thrombocytopenia, ul-
cerative stomatitis and coagulopathy (Additional file 2:
Table S1, Fig. 1).
The treatment or follow-up period was reported ad-
equately in 14/15 (93%) studies (Additional file 2: Table S1).
From these, in 9/14 (60%) the follow-up time was short (<6
months). Dose and serum levels were provided adequately
in 13/15 (87%) and 11/15 (73%) studies respectively
(Additional file 2: Table S1). The phenobarbital main-
tenance doses and serum levels were higher than the
normal reference range [6] in 8/13 (62%) and 4/11
(36%) studies respectively. In all, type I and II adverse
effects did not follow a dose or serum levels dependent
pattern. In summary, the level of evidence for pheno-
barbital’s efficacy and safety profile was weak.
Potassium Bromide
Three studies [21, 28, 36] assessed potassium bromide’s
efficacy as a monotherapy agent or in combination to
phenobarbital (one study), providing a total group size
Fig. 3 Proportion of adverse effects for levetiracetam. Each adverse
effect represents the percentage of cats that were affected by this
with regards to the overall combined population for levetiracetam.
The blue bars indicate type I adverse effects
Fig. 4 Proportion of specific adverse effects for imepitoin. Each
adverse effect represents the percentage of cats that were affected
by this with regards to the overall combined population for imepitoin.
The blue bars indicate type I adverse effects
Fig. 2 Proportion of specific adverse effects for potassium bromide.
Each adverse effect represents the percentage of cats that were
affected by this with regards to the overall combined population for
potassium bromide. The blue and red bars indicate type I and II
adverse effects, respectively
Fig. 1 Proportion of specific adverse effects for phenobarbital.
Each adverse effect represents the percentage of cats that were
affected by this with regards to the overall combined population
for phenobarbital. The blue and red bars indicate type I and II
adverse effects, respectively
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of 29 cats. Based on the 95% CI, in all the studies but
one [21] (66%), the majority of the study population was
treated successfully.
Six studies [21, 28, 36–39] evaluated the safety profile
of potassium bromide, providing a total size of 72 cats.
One of these studies included both a UCT and retro-
spective case series part [21]. One study documented
type I adverse effects, such as neurological, GI signs and
PD. Five studies reported type II adverse effects, such as
respiratory and dermatological signs (Table 2). One study
reported that there were no adverse effects. Applying the
95% CI, in all the studies (100%), the majority of the cases
reported did not have adverse effects. The most common
adverse effect was cough and least common were derma-
titis/bromoderma, vomiting, weight gain and PD (Table 2,
Fig. 2).
Treatment or follow-up time was reported adequately
in 6/7 (86%) (Table 2). From these, in 2/6 (33%) the
period was short (<6 months). The dose and serum
levels were documented adequately in 4/7 (57%) and 3/7
(43%) studies (Table 2). There was no adequate informa-
tion to relate specific range values of dose and serum
levels with the development of type I or II adverse ef-
fects. In summary, the level of evidence for potassium
bromide’s efficacy and safety profile was weak.
Levetiracetam
Four studies [26, 30, 40, 41] assessed the efficacy of leve-
tiracetam as a monotherapy agent or in combination to
phenobarbital (three studies), providing a total group
size of 43 cats. Based on the 95% CI, in two of the stud-
ies [26, 30] (50%), the majority of the study population
was treated successfully.
Five studies [26, 40–43] reported the safety profile of
levetiracetam, providing a total group size of 67 cats.
Only type I adverse effects were reported in all evaluated
studies, including neurological and GI signs and clinico-
pathological abnormalities (Table 2). Based on the 95% CI,
in all of the studies but one [42] (75%), the majority had
no adverse effects reported. One study reported no ad-
verse effects [43]. The most common adverse effect was
hypersalivation and the least common was PD (Table 2,
Fig. 3).
The treatment or follow-up time was reported adequately
in all the studies (Table 2), but was short (<6 months)
in 5/6 (83%). The dose and serum levels were reported
adequately in 6/6 (100%) and 4/6 (66%) studies re-
spectively (Table 2). The levetiracetam maintenance
doses reported were higher than normal in 2/6 (33%)
studies. In all, type I adverse effects did not follow a
dose or serum levels dependent pattern. The level of
evidence for levetiracetam’s efficacy and safety profile
was weak.
Imepitoin
One study [20] assessed the efficacy of imepitoin as
monotherapy agent in 8 cats. With such a small popula-
tion size studied the 95% CI could not demonstrate that
the majority of cases were managed successfully.
Three studies, which were included as part of one report
[20], reported the safety profile of imepitoin, providing a
total study size of 19 cats. In one study, only type I adverse
effects were reported including neurological, GI signs and
PD or decreased water consumption. In the two other
studies though, no such effects were reported but inter-
mittent vomiting, hypersalivation and slightly decreased
appetite (Table 3). Applying the 95% CI to all study data
(100%), the majority of cases did not experience adverse
effects. There was an equal distribution among all the ad-
verse effects (Table 3, Fig. 4).
The treatment or follow-up time was reported ad-
equately in all studies (Table 3). In all studies (100%) the
period was short (<6 months). The dose and serum levels
was provided adequately in 3/3 (100%) and 0/3 (0%) stud-
ies, respectively (Table 3). Higher imepitoin maintenance
doses, i.e. 40 or 80 mg/kg PO BID, were associated with
higher incidence of adverse effects. The level of evidence
for imepitoin’s efficacy was weak but the level of evidence
for safety profile was strong.
Diazepam
One study [44] assessed the efficacy of diazepam as
monotherapy. The study reported that the majority of
the cases was managed successfully, but the 95% CI
could not be calculated.
Three studies [44–46] reported the safety profile of
diazepam, providing a total size of 16 cats. One study
documented type I adverse effects, i.e. neurological
signs (Table 3). Two studies documented type II ad-
verse effects, i.e. GI signs (Table 3). One study reported
that there were no adverse effects. Since all the studies,
but one [44], selectively included cats that manifested
adverse effects, the 95% CI and adverse effects preva-
lence could not be calculated (Table 3).
The treatment or follow-up time was reported ad-
equately in 3/3 (100%), but was considered short in all
(Table 3). The dose and serum levels were reported ad-
equately in 3/3 (100%) and 0/3 (0%) studies respectively
(Table 3). In all, type I and II adverse effects did not fol-
low a dose or serum levels dependent pattern. The level
of evidence for diazepam’s efficacy and safety profile was
weak.
Primidone
One study [44] assessed the efficacy of primidone as a
monotherapy agent in 6 cats. Applying the 95% CI to
such a small study population showed that the majority
was not managed successfully.
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Two studies [44, 47] reported the safety profile of pri-
midone, providing a total group size of 17 cats. The
studies reported type I adverse effects, such as GI and
neurological signs and weight loss. No type II adverse ef-
fects were reported (Table 3). Applying the 95% CI to
one study [44] (50%), the majority of cases did not have
adverse effects reported. The most common adverse ef-
fect was sedation and the least common were anorexia
and weight loss (Table 3).
The treatment or follow-up period was reported ad-
equately in 2/2 (100%) (Table 3). From these, in 1/2
(50%) the period was short (<6 months). The dose and
serum levels was reported adequately in 2/2 (100%) and
1/2 (50%) studies respectively (Table 3). There was inad-
equate information to relate specific range values of dose
and serum levels with the development of type I or II
adverse effects. The level of evidence for primidone’s ef-
ficacy and safety profile was weak.
Phenytoin
One study [44] evaluated the efficacy of phenytoin as an
adjunct to diazepam in 2 cats.
Two studies [44, 48] reported the safety profile of
phenytoin, providing a total size of 6 cats. The studies
documented type I adverse effects, such as GI and
neurological signs and clinic-pathological abnormalities.
No type II adverse effects were documented (Table 3).
Based on the 95% CI, in all the studies (100%), the ma-
jority of the study population experienced adverse ef-
fects. The most common adverse effect was anorexia
and the least common was increased serum liver en-
zymes (Table 3).
The treatment or follow-up period was reported ad-
equately in 2/2 (100%) (Table 3). From these, in 1/2 (50%)
the period was short (<6 months). The dose and serum
levels were reported adequately in 2/2 (100%) studies
(Table 3). There was inadequate information to relate
specific range values of dose and serum levels with the
development of type I or II adverse effects. The level of
evidence for phenytoin’s efficacy and safety profile was
weak.
Zonisamide
One study [49] assessed the efficacy of zonisamide as an
adjunct to phenobarbital in 5 cats. Applying the 95% CI
to such a small study population showed that the major-
ity was not managed successfully.
Three studies [49–51] reported the safety profile of
zonisamide in 19 cats. The studies documented type I
adverse effects, such as GI and neurological signs
(Table 4). Based on the 95% CI, in all studies (100%),
the majority of the study population did not have adverse
effects. One study reported no adverse effects [51]
The treatment or follow-up time was reported ad-
equately but was considered short in all studies (Table 4).
The dose and serum levels were also reported adequately
in all studies (Table 4). There was inadequate information
to relate specific range values of dose and serum levels
with the development of type I or II adverse effects. In
summary, the level of evidence for zonisamide’s efficacy
and safety profile was weak.
Pregabalin
There were no original studies evaluating the efficacy of
pregabalin in cats except for experts’ opinion. One study
[52] reported the safety profile of pregabalin in 6 cats.
The study documented type I adverse effects, i.e. neuro-
logical signs. No type II adverse effects were documented
(Table 4). Applying the 95% CI to the studied population,
the majority did not experience adverse effects.
The treatment or follow-up time was inadequately
reported (Table 4). The dose and serum levels was re-
ported adequately (Table 4). There was inadequate in-
formation to relate specific range values of dose and
serum levels with the development of type I or II ad-
verse effects. There was no evidence for pregabalin’s
efficacy and an overall weak level of evidence for preg-
abalin’s safety profile.
Valproic acid
There were no original studies evaluating the efficacy of
valproic acid in cats except for experts’ opinion. Three
studies [53–55] reported the safety profile of valproic
acid, giving a combined sample size of 15 cats. Three
studies documented type I adverse effects, such as GI
and neurological signs. One study documented type II
adverse effects, i.e. dermatological signs (Table 4). There
was inadequate information to calculate the 95% CI but
one study [55] showed that the whole population had
adverse effects. The most common adverse effects were
sedation ataxia, drowsiness, head tremor and anorexia
and the least common were hyperactivity and alopecia.
The treatment or follow-up time was reported ad-
equately in 2/3 (67%) studies and was considered short.
The dose and serum levels were reported adequately in
3/3 (100%) (Table 4). There was inadequate information
to relate specific range values of dose and serum levels
with the development of type I or II adverse effects.
There was no evidence for valproic acid’s efficacy and
weak level of evidence for safety profile.
Discussion
To the authors’ knowledge, this is the first systematic re-
view of AEDs’ efficacy and safety in cats. The authors
were based on the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) statement to
report this systematic review [56]. The systematic review
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found that the level of evidence in feline epilepsy treat-
ment is weak to absent, in particular for AEDs’ efficacy.
The results showed that phenobarbital was considered
the most effective AED followed by levetiracetam and
potassium bromide, then imepitoin and diazepam and
lastly zonisamide, primidone and phenytoin (Fig. 5). All
supported by weak level of evidence. There was insuffi-
cient evidence for the efficacy of pregabalin and valproic
acid. As far as the safety profile of all the AEDs is con-
cerned, imepitoin was considered the safest AED, followed
by levetiracetam and phenobarbital, then zonisamide and
pregabalin followed by primidone, phenytoin and valproic
acid and lastly potassium bromide and diazepam (Fig. 6).
All supported by weak level of evidence apart from imepi-
toin, which was supported by good level of evidence. Al-
though this systematic review focused on evaluating the
use of AEDs in feline patients, it would be an omission
not to mention that other substances have been proposed
for managing seizures in cats [57, 58], with taurine as the
most representative example. In a feline case report, ad-
ministration of 300 mg taurine subcutaneously twice a day
for two days followed by 100 mg taurine orally once a day
for one month resulted in reduction in seizure frequency,
supported by clinical and electroencephalographic obser-
vations. Abrupt cessation led to a rise of frequency [57].
Further clinical studies are crucial to support taurine’s
potential efficacy in feline epilepsy.
The AEDs’ adverse effects were categorised as type I
(predictable or dose-dependent) or type II (idiosyncratic/
unpredictable or dose-independent) which are usually
considered as non-immunological reactions [59]. It was
challenging to detect a correlation between the AED
dose or serum concentration and the type of adverse ef-
fects in feline patients. This could be attributed either to
the possibility that, in feline patients, adverse effects
might not follow a dose or serum related pattern or to
the fact that there was inadequate information to allow
us assessing any potential correlation between the inci-
dence of adverse effects and the AEDs’ dose or serum
concentrations. Severe type II adverse effects were re-
ported mainly in cats being treated with potassium brom-
ide or diazepam. Type II adverse effects are non-dose
dependent, unpredictable, usually rare and caused by a cy-
totoxin, a drug or its metabolite [59]. Idiosyncratic reac-
tions are most likely secondary to an individual difference
in rate of formation and detoxification of reactive metabo-
lites [59]. However, in the case of potassium bromide and,
in particular, diazepam in feline patients, the incidence of
these type II effects was high and in case of diazepam, they
were considered life-threatening. This can give rise to evi-
dence that the type II adverse effects of these two drugs in
cats are species-related rather than individual-related.
In canine epilepsy, the majority of studies lacked a
high level of evidence [8, 15]. However, in feline epilepsy,
almost none of the studies provided high quality of evi-
dence. The studies manifested high overall risk of bias.
In addition, only 47% and 2% of all studies had well
clinically defined groups and assessed a sufficient num-
ber of cats, respectively. The 95% CI, that was used as
an indicator of the ‘real’ population of successful (AED
efficacy) or affected (AED safety) cases, revealed a wide
range of values mainly due to the inadequate feline
population in the studies. Therefore, conclusions drawn
based on the 95% CI results should be interpreted with
caution. In addition, there were no bRCTs evaluating
any AEDs in cats but two bRELAS assessing imepitoin’s
safety profile. The follow up time was rather limited
and short (<6months) to assess adequately long-term
efficacy and tolerability. In all, due to the lack of studies
with overall low risk of bias, insufficient disease charac-
terisations and small group sizes, clear suggestions con-
cerning AEDs’ efficacy and safety are difficult.
In contrast to canine epilepsy, many studies evaluated
the efficacy and safety of an AED as monotherapy (with
the exception of levetiracetam), making it easier to de-
termine whether an AED’s adverse effects and efficacy
were attributed mainly to its administration. However,
Fig. 6 Pyramid of AEDs’ safety hierarchy based on the quality of
evidence and outcomes assessment
Fig. 5 Pyramid of AEDs’ efficacy hierarchy based on the quality of
evidence and outcomes assessment
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certain evaluated factors might have influenced our as-
sessment of AEDs’ efficacy and safety profile similar to
the ones described in our previous systematic reviews
for canine patients [8, 15]. These included the dosages
used of a particular AED (i.e. different among studies),
the frequency of AEDs’ administration (i.e. factor that
could alter the chances of occurrence of adverse effects
particularly in AEDs with short half-life due to fluctua-
tions of serum drug levels; although this characteristic
might not affect the results [60]), the duration of the
study (i.e. insufficient duration, as it was found in many
studies, might have reduced the chance for the most fre-
quent adverse effects to occur or for adequately evaluate
an AED’s efficacy). Lastly, a few AEDs have been used
more often in feline epilepsy and been in the market for
longer period compared to others. Therefore, more evi-
dence is available which could influence the conclusions
with regards to their efficacy and safety. A characteristic
example is phenobarbital for which, compared to other
AEDs, there are more reports of not only its efficacy but
also its adverse effects.
As it was found in the previous canine systematic re-
views and meta-analysis [8, 15], some characteristics
may have also adversely affected the evaluation of the
included studies. Similarly, multiple factors could have
influenced our results such as signalment differed between
studies, heterogeneity in treatment methods among stud-
ies, variation in study publication dates, publication bias,
several introduced biases detected, lack of high quality
evidence studies (i.e. bRCTs and bRELAS), lack of well
characterized diagnostic procedures and enrolment of
relatively small study population.
Implications for research
Systematic reviews are a good step towards clinical evi-
dence medicine, however the evaluation and comparison
among AEDs through a meta-analysis could provide far
further information and aid clinician’s decision to choose
the most appropriate AED for every patient. A meta-
analysis was not feasible here due to the variations in
baseline characteristics of the cats involved, the significant
differences between study designs, the several sources of
identified bias and mainly due to the lack of comparison
group studies. Although the 95% CI and the prevalence of
successfully treated cases and adverse effects in each study
provide a general indicator of each AED’s efficacy and
safety profile, respectively, and can lead to indirect com-
parisons between AEDs, comparison group studies are es-
sential as they allow thorough statistics to be performed
for direct and thus more reliable comparisons. Therefore,
further comparison groups and blinded randomized stud-
ies are essential for feline epilepsy treatment that would
allow a meta-analysis towards this goal.
Lastly, a further problem that was found during the
studies evaluation was the lack of reported information.
This led to difficulties in performing statistical analysis
for AEDs’ comparisons. Therefore, it is essential that
future trials should provide precise information and sci-
entists have open access to trials’ data. It would be cru-
cial that journals enforce authors to report their results
based on guidelines such as STROBE (Strengthening
the Reporting of Observational studies in Epidemiology),
ARRIVE (Animal Research: Reporting of In Vivo Exper-
iments) and CONSORT (Consolidated Standards of
Reporting Trials).
Implications for clinical practice
Current evidence did not allow comparisons among
AEDs, and therefore it would be rather inaccurate to make
definite statements on which one should be considered as
a first or second choice in terms of both efficacy and
safety profile. However, if clinicians focus on AED’s effi-
cacy, phenobarbital can be used as first-choice monother-
apy and if they focus on AED’s safety, imepitoin or
levetiracetam can be used. It is important to report that,
similarly to canine epilepsy [8], phenobarbital should not
be overstated as an AED with high incidence of detrimen-
tal adverse effects and therefore, in healthy cats with no
pre-existing liver disease, phenobarbital might be the most
appropriate choice. Levetiracetam or imepitoin can also
be considered as a safe alternative for monotherapy, espe-
cially in cats that develop unexpected adverse effects to
phenobarbital. For certain epilepsy phenotypes, such as
myoclonic epilepsy in elderly cats, levetiracetam mono-
therapy can be considered. Levetiracetam, imepitoin or
phenorbarbital and, to a quite lesser degree, zonisamide
might be considered as add-on medication when first line
treatment chosen is not sufficient to control seizures. Po-
tassium bromide can be used as adjunctive AEDs only as
a last resort and after a signed owner’s consent form in
cases manifesting resistance to >2 AEDs and should be
closely monitored for type II adverse effects. Diazepam
might not be an appropriate choice due to the inadequate
evidence supporting its efficacy and the possibility of se-
vere and potentially life-threatening type II adverse effects.
It is also important to note that the recommendations
made are on the basis of the evidence provided in the
available literature and local drug legislation need to be
considered prior of prescribing medications.
In general, as it was found in our previous systematic
review [8], most of the AED adverse effects docu-
mented were inconsistent, fairly tolerable and not life-
threatening and ceased once doses and serum levels
were decreased or following drug withdrawal. Exceptions
included specific type II adverse effects and specific anti-
epileptic drugs (in particular diazepam and to a lesser de-
gree potassium bromide). It is essential that clinicians
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assess both the benefits (i.e. value for money, dosing regi-
men, efficacy) and risks (i.e. safety and tolerability, and im-
pact of adverse effects on the cat’s and owner’s quality of
life) before choosing a specific AED.
Conclusion
This systematic review provides an evidence-based as-
sessment of the data on the AEDs’ efficacy and adverse
effects for feline epilepsy. Factors that need to be consid-
ered when evaluating these results are: i) drugs that have
been used and been on the market for longer periods
provided more evidence, ii) the vast majority of the studies
offered overall high risk of bias and included small num-
ber of cats with unclear or fair disease characterization
criteria and short-term follow-up. Individual AED assess-
ments of efficacy and safety profile showed that phenobar-
bital can be used as the first-choice AED followed by
imepitoin and levetiracetam. Further studies in feline epi-
lepsy treatment are by far essential in order to establish
definite guidelines for AEDs’ efficacy and safety.
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